DISCOUNT OPTIONSSCHEIN - MODERNA | Market Closed - Deutsche Boerse AG 01:44:44 2024-05-28 pm EDT | ||
| 0.49 EUR | -57.39% |
|
| Current month | +807.41% | ||
| 1 month | +1,125.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-28 | 0.49 | -57.39% |
| 24-05-27 | 1.15 | -7.26% |
| 24-05-24 | 1.24 | +21.57% |
| 24-05-23 | 1.02 | +14.61% |
| 24-05-22 | 0.89 | +312.04% |
Delayed Quote Deutsche Boerse AG
Last update May 28, 2024 at 01:44 pm EDT
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| WKN | VU1SXF |
| ISIN | DE000VU1SXF9 |
| Date issued | 2023-01-05 |
| Strike | 160 $ |
| Maturity | 2024-06-21 (24 Days) |
| Parity | 10 : 1 |
| Emission price | 1.53 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.4 € |
|---|---|
| Lowest since issue | 0.024 € |
| Spread | 0.01 € |
| Spread % | 1.75% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
153.2
USD
Average target price
138.5
USD
Spread / Average Target
-9.59%
- Stock Market
- Certificates
- Certificat
